Filter posts

Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

Claims of Gene-Edited Twins Met with Criticism and Concern

As the Second International Summit on Human Genome Editing wraps in Hong Kong this week, breaking …

Alzheimer’s Awareness Month: Hope on the Horizon

Did you know that more than 5 million Americans are currently living with Alzheimer’s disease? …

Survey Says: Solutions to Combat Against Antimicrobial Resistance Needed

Writing for The Hill, Dr. Cynthia Sears, president of the Infectious Diseases Society of America …

Patient and Health Advocacy Summit: Ensuring Patient Access and Affordability

In a world of continual innovation in biopharmaceuticals, how do we ensure patients have access …

Patient Advocates Sounding the Alarm Over Fail First

The Centers for Medicare & Medicaid Services (CMS) has reversed a long-standing policy allowing Medicare …

Drug Importation: Dangerous for Patients, Consumers, and American Communities

Writing for The Hill, Steve Forbes, Forbes Media Chairman and Editor in Chief, delivered a …

To Ensure History Does Not Repeat Itself, Get a Flu Shot

The Centers for Disease Control and Prevention (CDC) is out with shocking new data: an …

Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit …